Analysis of the efficacy of standard anticancer therapies in Japan.
Eighty patients with prostatic carcinoma were treated by antiandrogen therapy with chlormadinone acetate and diethylstilbestrol diphosphate. Numerous papers have shown that the survival rates of patients with low-grade prostatic carcinomas are higher than those of patients in advanced stages; however, in this study, no statistically significant difference in the ten-year survival rates of these groups was demonstrated. Residual cancer cells in the primary lesions were observed in 90% of the patients who underwent autopsy following death. The results of this study suggest that antiandrogen therapy is not sufficiently effective for the treatment of patients with prostatic carcinoma.